PipeLine
Tissue-agnostic Biomarker-based Innovative Drug Pipeline
MedPacto’s anticancer assets are developed to treat based on biomarker expression, which is agnostic to any specific tumor tissue type, and to combine with various therapeutic options
PipeLine
Type
Biomarker
Mode of Action
Vactosertib
Anticancer therapeutic
(Small molecule)
TBRS
TGF-ß receptor 1 kinase inhibitor
MA-B2
Anticancer therapeutic(Antibody)
Serum BAG2 protein
Anti-BAG2 antibody
MO-B2
Diagnostic
kit
Serum BAG2 protein
Serum BAG2 diagnostic kit
MU-D201
Anticancer therapeutic
(Small molecule)
EZH2 gene mutation,
gamma delta T-cell receptor
DRAK2 inhibitor